Gemzar (gemcitabine)
Phase 3UNKNOWN 0 views this week 0 watching💤 Quiet
Interest: 36/100
36
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Cervical Cancer
Conditions
Cervical Cancer
Trial Timeline
Feb 1, 2009 → Jan 1, 2013
NCT ID
NCT00842660About Gemzar (gemcitabine)
Gemzar (gemcitabine) is a phase 3 stage product being developed by Eli Lilly for Cervical Cancer. The current trial status is unknown. This product is registered under clinical trial identifier NCT00842660. Target conditions include Cervical Cancer.
What happened to similar drugs?
8 of 20 similar drugs in Cervical Cancer were approved
Approved (8) Terminated (0) Active (12)
Hype Score Breakdown
Clinical
17
Activity
4
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00842660 | Phase 3 | UNKNOWN |
Competing Products
20 competing products in Cervical Cancer